These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 17266937

  • 21. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.
    Lackenby A, Democratis J, Siqueira MM, Zambon MC.
    Antivir Ther; 2008; 13(6):809-20. PubMed ID: 18839782
    [Abstract] [Full Text] [Related]

  • 22. Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.
    Meeprasert A, Khuntawee W, Kamlungsua K, Nunthaboot N, Rungrotmongkol T, Hannongbua S.
    J Mol Graph Model; 2012 Sep; 38():148-54. PubMed ID: 23079644
    [Abstract] [Full Text] [Related]

  • 23. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
    Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA.
    PLoS Pathog; 2010 May 27; 6(5):e1000933. PubMed ID: 20523902
    [Abstract] [Full Text] [Related]

  • 24. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
    Liu H, Yao X, Wang C, Han J.
    Mol Pharm; 2010 Jun 07; 7(3):894-904. PubMed ID: 20420444
    [Abstract] [Full Text] [Related]

  • 25. Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues.
    Ho HT, Hurt AC, Mosse J, Barr I.
    Antiviral Res; 2007 Dec 07; 76(3):263-6. PubMed ID: 17868928
    [Abstract] [Full Text] [Related]

  • 26. Antiviral management of seasonal and pandemic influenza.
    Hayden FG, Pavia AT.
    J Infect Dis; 2006 Nov 01; 194 Suppl 2():S119-26. PubMed ID: 17163384
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
    Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG.
    Antiviral Res; 2007 Mar 01; 73(3):228-31. PubMed ID: 17112602
    [Abstract] [Full Text] [Related]

  • 29. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.
    Abed Y, Nehmé B, Baz M, Boivin G.
    Antiviral Res; 2008 Feb 01; 77(2):163-6. PubMed ID: 17919743
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
    Udommaneethanakit T, Rungrotmongkol T, Bren U, Frecer V, Stanislav M.
    J Chem Inf Model; 2009 Oct 01; 49(10):2323-32. PubMed ID: 19780597
    [Abstract] [Full Text] [Related]

  • 32. Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
    Xie Y, Xu D, Huang B, Ma X, Qi W, Shi F, Liu X, Zhang Y, Xu W.
    J Med Chem; 2014 Oct 23; 57(20):8445-58. PubMed ID: 25255388
    [Abstract] [Full Text] [Related]

  • 33. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
    Hayden F, Klimov A, Tashiro M, Hay A, Monto A, McKimm-Breschkin J, Macken C, Hampson A, Webster RG, Amyard M, Zambon M.
    Antivir Ther; 2005 Oct 23; 10(8):873-7. PubMed ID: 16430192
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Inhibition of viral group-1 and group-2 neuraminidases by oseltamivir: A comparative structural analysis by the ScrewFit algorithm.
    Calligari PA, Kneller GR, Giansanti A, Ascenzi P, Porrello A, Bocedi A.
    Biophys Chem; 2009 Apr 23; 141(1):117-23. PubMed ID: 19195766
    [Abstract] [Full Text] [Related]

  • 36. Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.
    Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, Webster RG.
    PLoS Pathog; 2008 Apr 11; 4(4):e1000043. PubMed ID: 18404209
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S, Takashita E, Yokoyama M, Taniwaki T, Xu H, Kishida N, Sato H, Tashiro M, Imai M, Odagiri T.
    Biochem Biophys Res Commun; 2012 Dec 07; 429(1-2):51-6. PubMed ID: 23131559
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.